Date of issue: 
Fulfilling the vision treatment of many incurable diseases by the use of continuously proliferating and differentiating into all tissues of the body of human embryonic stem cells ( HP) has so far not gone beyond the experimental stage preclinical studies . Numerous attempts to apply for the same purposes somatic HP derived from mature tissue yielded only moderate clinical effects . The article presents the basic difficulties which slow down the development of cell therapy . Do not lie solely in the realm of ethical or legal issues , but serious and still unresolved biological hazards ( genomic instability , tumorogenność ) in the case of embryonic hp and insufficient knowledge of the mechanisms that regulate the proliferation and differentiation also targeted hp coming from mature tissue . Results so far very intensive research are undoubtedly encouraging, but the prospects for their complete solutions depend on unpredictable in the time scale of the progress of our knowledge of the basic biology of HP .
Author of the article: 

The Editorial Board
Andrzej Łukaszyk - przewodniczący, Zofia Bielańska-Osuchowska, Szczepan Biliński, Mieczysław Chorąży, Aleksander Koj, Włodzimierz Korochoda, Leszek Kuźnicki, Aleksandra Stojałowska, Lech Wojtczak

Editorial address:
Katedra i Zakład Histologii i Embriologii Uniwersytetu Medycznego w Poznaniu, ul. Święcickiego 6, 60-781 Poznań, tel. +48 61 8546453, fax. +48 61 8546440, email:

PBK Postępby biologi komórki